Nye data viser, at patienter med metatastisk colorectal cancer af KRAS- vildtypen har en signifikant højere chance for at få gavn af behandling med cetuximab eller en kombination af cetuximab og kemoterapi.
Recent data demonstrate that patients with KRAS wild-type metastatic colorectal cancer have a significantly higher chance to benefit from treatment with cetuximab or a combination of cetuximab and chemotherapy.